BIOCORP Signs an Agreement with Merck KGaA to Co-develop New Bluetooth-Enabled Drug Delivery Device
Shots:
- BIOCORP will receive ~$4.85M for the product development within the first 3yrs. of the collaboration along with additional revenues of ~$7.76M during the first 5yrs. after launch, following completion of milestones & adoption of Mallya devices
- The companies collaborated to develop & supply a specific version of a Mallya device/ Mallya is a pen injector clip-on device with Bluetooth capabilities that records the dose & timing of each inj. and transmits that data in real time to companion software
- The device received a CE mark while the commercial insulin pen injectors are distributed in the EU & other regions. BIOCORP signed agreements with Sanofi, Novo Nordisk & Merck KGaA to develop specialized versions of the technology for insulin & HGH
Ref: BIOCORP | Image: BIOCORP
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
